<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02010333</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-003</org_study_id>
    <nct_id>NCT02010333</nct_id>
  </id_info>
  <brief_title>A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation</brief_title>
  <official_title>A Pediatric Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate safety and tolerability of a single&#xD;
      application of Ha44 Gel 0.74% w/w for the treatment of head lice. Secondary purpose is to&#xD;
      evaluate PK of Ha44 and benzyl alcohol under conditions of maximal exposure in pediatric&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Ha44 Gel</measure>
    <time_frame>8 months</time_frame>
    <description>Clinically significant changes in Physical Examinations, vital signs, safety laboratory tests and assessments of scalp and eye irritation and Electrocardiogram. The frequency and severity of Adverse Events.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Head Lice Infestation</condition>
  <arm_group>
    <arm_group_label>Ha44 Gel 0.74% w/w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, one arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44 Gel 0.74% w/w</intervention_name>
    <description>HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.</description>
    <arm_group_label>Ha44 Gel 0.74% w/w</arm_group_label>
    <other_name>Abametapir 0.74%</other_name>
    <other_name>Benzyl Alcohol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 6months &lt; 3years of age&#xD;
&#xD;
          2. Good health&#xD;
&#xD;
          3. Active head lice infestation defined as the presence of at least 3 live lice&#xD;
&#xD;
          4. Dermatological condition of scalp (at least G2 erythema or pruritus with evidence of&#xD;
             excoriation/inflammation)&#xD;
&#xD;
          5. Parent/guardian agrees to allow PK samples collected&#xD;
&#xD;
          6. Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Condition or illness that in the opinion of the investigator may interfere with the&#xD;
             study results.&#xD;
&#xD;
          2. Current dermatological disease that may compromise the health of subject or the&#xD;
             assessment of safety. Subjects with scalp ulceration or evidence of scalp infection&#xD;
             should not be enrolled.&#xD;
&#xD;
          3. Prior reaction to product containing piperonyl butoxide, pyrethrin, or pyrethrum&#xD;
             extract.&#xD;
&#xD;
          4. Receiving systemic or topical medication that may interfere the study results.&#xD;
&#xD;
          5. Received an investigational agent within 30 days prior to Day 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universal Biopharma Research Institute</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <disposition_first_submitted>August 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2015</disposition_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Mite Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzyl Alcohol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

